Bazedoxifene for the prevention of postmenopausal osteoporosis

Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti

Research output: Contribution to journalArticle

Abstract

Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and without stimulating the uterus or the breast. In both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine profile and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter capacity has led to the development of a novel class of menopausal therapy called tissue selective estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus, without aggravating menopausal vasomotor symptoms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear to confirm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to raloxifene, coupled with efficacy on menopausal vasomotor symptoms not achieved by SERM alone. These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders.

Original languageEnglish
Pages (from-to)1229-1242
Number of pages14
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number6
Publication statusPublished - 2008

Fingerprint

bone disease
Postmenopausal Osteoporosis
Selective Estrogen Receptor Modulators
Estrogens
Tissue
Modulators
Uterus
Breast
menopause
Women Physicians
Conjugated (USP) Estrogens
Phase III Clinical Trials
Progestins
Menopause
Cell- and Tissue-Based Therapy
Endometrium
Lipid Metabolism
Skeleton
physician
Screening

Keywords

  • Bazedoxifene
  • Estrogen
  • Postmenopausal osteoporosis
  • SERM
  • Treatment

ASJC Scopus subject areas

  • Chemical Health and Safety
  • Medicine(all)
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research

Cite this

Gennari, L., Merlotti, D., De Paola, V., Martini, G., & Nuti, R. (2008). Bazedoxifene for the prevention of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management, 4(6), 1229-1242.

Bazedoxifene for the prevention of postmenopausal osteoporosis. / Gennari, Luigi; Merlotti, Daniela; De Paola, Vincenzo; Martini, Giuseppe; Nuti, Ranuccio.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 6, 2008, p. 1229-1242.

Research output: Contribution to journalArticle

Gennari, L, Merlotti, D, De Paola, V, Martini, G & Nuti, R 2008, 'Bazedoxifene for the prevention of postmenopausal osteoporosis', Therapeutics and Clinical Risk Management, vol. 4, no. 6, pp. 1229-1242.
Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. Bazedoxifene for the prevention of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management. 2008;4(6):1229-1242.
Gennari, Luigi ; Merlotti, Daniela ; De Paola, Vincenzo ; Martini, Giuseppe ; Nuti, Ranuccio. / Bazedoxifene for the prevention of postmenopausal osteoporosis. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 6. pp. 1229-1242.
@article{dc51c94cfe4b471d98d971671334f803,
title = "Bazedoxifene for the prevention of postmenopausal osteoporosis",
abstract = "Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and without stimulating the uterus or the breast. In both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine profile and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter capacity has led to the development of a novel class of menopausal therapy called tissue selective estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus, without aggravating menopausal vasomotor symptoms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear to confirm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to raloxifene, coupled with efficacy on menopausal vasomotor symptoms not achieved by SERM alone. These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders.",
keywords = "Bazedoxifene, Estrogen, Postmenopausal osteoporosis, SERM, Treatment",
author = "Luigi Gennari and Daniela Merlotti and {De Paola}, Vincenzo and Giuseppe Martini and Ranuccio Nuti",
year = "2008",
language = "English",
volume = "4",
pages = "1229--1242",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Bazedoxifene for the prevention of postmenopausal osteoporosis

AU - Gennari, Luigi

AU - Merlotti, Daniela

AU - De Paola, Vincenzo

AU - Martini, Giuseppe

AU - Nuti, Ranuccio

PY - 2008

Y1 - 2008

N2 - Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and without stimulating the uterus or the breast. In both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine profile and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter capacity has led to the development of a novel class of menopausal therapy called tissue selective estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus, without aggravating menopausal vasomotor symptoms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear to confirm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to raloxifene, coupled with efficacy on menopausal vasomotor symptoms not achieved by SERM alone. These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders.

AB - Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and without stimulating the uterus or the breast. In both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine profile and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter capacity has led to the development of a novel class of menopausal therapy called tissue selective estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a progestin in women with an intact uterus, without aggravating menopausal vasomotor symptoms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear to confirm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to raloxifene, coupled with efficacy on menopausal vasomotor symptoms not achieved by SERM alone. These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders.

KW - Bazedoxifene

KW - Estrogen

KW - Postmenopausal osteoporosis

KW - SERM

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=61549094100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549094100&partnerID=8YFLogxK

M3 - Article

C2 - 19337430

AN - SCOPUS:61549094100

VL - 4

SP - 1229

EP - 1242

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 6

ER -